Gᵢ/o protein

Gᵢ/o protein. The Gᵢ/o protein family is a major subgroup of heterotrimeric G proteins, defined by their sensitivity to inhibition by pertussis toxin and their primary coupling to the inhibition of adenylyl cyclase. These proteins are ubiquitously expressed in the central nervous system and are critical mediators of signaling for a vast array of G protein-coupled receptors, influencing processes from neurotransmission to cardiac function. Their activity is pivotal in modulating cellular responses to numerous hormones and neurotransmitters, making them central to both physiological homeostasis and disease pathology.

Structure and classification

Gᵢ/o proteins are heterotrimers composed of Gαᵢ, Gαₒ, or Gαᵣ subtypes, a Gβ subunit, and a Gγ subunit. The defining Gα subunits are encoded by distinct genes, including GNAI1, GNAI2, GNAI3, and GNAO1, which are substrates for ADP-ribosylation catalyzed by pertussis toxin. This modification uncouples the G protein from its cognate G protein-coupled receptor. The Gβγ complex is also essential for function and can independently regulate effectors like G protein-coupled inwardly-rectifying potassium channels. Classification within this family is based on amino acid sequence homology and functional coupling, with Gαᵢ isoforms primarily inhibiting adenylyl cyclase, while Gαₒ is highly abundant in the brain and additionally regulates ion channels and phospholipase C pathways.

Signaling mechanisms

Activation begins when an agonist, such as acetylcholine acting on M2 receptors or adenosine on A1 receptors, binds to the G protein-coupled receptor, inducing a conformational change. This promotes the exchange of GDP for GTP on the Gα subunit, leading to dissociation of the Gα-GTP complex from the Gβγ dimer. The liberated Gαᵢ/o-GTP directly inhibits isoforms of adenylyl cyclase, reducing intracellular cyclic AMP levels and the activity of protein kinase A. Simultaneously, the free Gβγ complex can directly open GIRK channels to hyperpolarize neurons, inhibit voltage-gated calcium channels like N-type calcium channels, and activate phosphoinositide 3-kinase and certain isoforms of phospholipase Cβ.

Physiological functions

Gᵢ/o proteins mediate a vast range of physiological responses. In the nervous system, they are crucial for presynaptic inhibition, regulating the release of neurotransmitters such as GABA and glutamate via inhibition of voltage-gated calcium channels. They mediate the vagus nerve's negative chronotropic and inotropic effects on the heart through M2 receptor coupling. In sensory systems, they participate in phototransduction in retinal rod cells and olfaction. They also modulate immune cell chemotaxis, platelet aggregation, and insulin secretion from pancreatic beta cells, highlighting their systemic importance.

Regulation and modulation

The intrinsic GTPase activity of the Gα subunit hydrolyzes GTP to GDP, terminating signaling by promoting reassociation with Gβγ. This activity is dramatically accelerated by Regulator of G protein signaling proteins, such as RGS4 and RGS7. Phosphorylation by G protein-coupled receptor kinases can promote receptor desensitization. Furthermore, Gᵢ/o signaling is exogenously modulated by bacterial toxins; pertussis toxin causes persistent inhibition, while cholera toxin can ADP-ribosylate other Gα subtypes to alter cross-talk. Several anesthetics and opioid drugs, like morphine acting on μ-opioid receptors, exert their effects primarily through Gᵢ/o protein activation.

Pathophysiological relevance

Dysregulation of Gᵢ/o signaling is implicated in numerous diseases. Mutations in GNAO1 are linked to severe pediatric disorders including early infantile epileptic encephalopathy and chorea. Overactive Gᵢ signaling contributes to the pathogenesis of heart failure and certain cancers by promoting uncontrolled cell proliferation. In the context of addiction, drugs like heroin and cocaine induce neuroadaptations in mesolimbic pathway signaling involving Gᵢ/o-coupled receptors. Furthermore, impaired Gᵢ/o function is observed in mood disorders and schizophrenia, influencing the efficacy of antipsychotic and antidepressant medications that target related G protein-coupled receptor systems.

Category:Heterotrimeric G proteins